Skip to main content

Table 5 Tumour-to-liver (SUVmax/SUVmean), by peptide mass and radioactivity range

From: A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

  Peptide mass range Radioactivity range
Organ Statistic 5–20 µg (N = 24) 30–45 µg (N = 24) 40–80 MBq (N = 16) 100–140 MBq (N = 16) 160–200 MBq (N = 16)
Primary tumour site n 6 5 3 5 3
Mean ± SD 32.1 ± 39.22 29.2 ± 28.01 41.4 ± 53.08 30.1 ± 27.67 21.3 ± 27.78
Median (range) 12.6 (4.94–102.40) 16.5 (5.57–64.98) 16.2 (5.67–102.40) 16.5 (5.31–64.98) 5.6 (4.94–53.36)
Liver n 18 18 13 10 13
Mean ± SD 11.5 ± 10.51 13.6 ± 11.72 12.9 ± 9.94 13.0 ± 11.87 11.8 ± 12.20
Median (range) 8.6 (3.28–40.14) 8.4 (5.08–48.79) 9.9 (5.60–37.00) 7.7 (4.85–40.14) 7.0 (3.28–48.79)
Lymph nodes n 14 14 8 9 11
Mean ± SD 13.2 ± 8.52 13.1 ± 8.98 13.8 ± 9.78 13.7 ± 8.93 12.3 ± 8.18
Median (range) 10.1 (4.42–27.43) 8.6 (2.26–28.98) 8.6 (5.56–28.98) 10.8 (4.42–26.46) 9.8 (2.26–25.14)
  1. n corresponds to the number of patients with lesions in either the primary tumour site, liver, or the lymph nodes
  2. The number of patients with lesions in the bones and lungs was too small (≤ 1 in each category) to allow a meaningful interpretation of PET/CT scans for these organs
  3. CT computed tomography, PET positron emission tomography, SD standard deviation, SUV standardised uptake value